Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2015-12-18 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于控股股东股权质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge of shares by the controlling shareholder of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the number of shares pledged, the pledgee, and the pledge period. There is no financial report, earnings data, or management discussion. The document is a formal disclosure of a capital-related event (share pledge) by a major shareholder. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share pledges.
2015-12-18 Chinese
关于使用自有资金增资成都金凯生物技术有限公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the use of its own funds to increase capital in its controlled subsidiary, Chengdu Jinkai Biotechnology Co., Ltd. It details the investment overview, board approval, investment purpose, risks, and financial data of the subsidiary. The document is a formal public announcement about a capital increase transaction, including shareholding changes and financial impact, but it does not contain comprehensive financial statements or detailed financial performance analysis typical of an annual or interim report. It is not a full financial report but rather a capital/financing update about the company's investment and capital structure change in a subsidiary. The document length is 2447 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2015-12-02 Chinese
第三届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution regarding the company's decision to increase capital investment in a subsidiary. It details the board meeting date, attendance, voting results, and authorization for the general manager to execute the investment. There are no financial statements or detailed financial performance data presented. The document is a formal announcement of a board/management decision rather than a full report or financial disclosure. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2015-12-02 Chinese
关于全资子公司收购深圳市科奕顿生物医疗科技有限公司股权暨增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the acquisition of a 60% equity stake in Shenzhen Keyidun Biomedical Technology Co., Ltd. by a wholly-owned subsidiary of Shenzhen Salubris Pharmaceuticals Co., Ltd., along with a planned capital increase. It details the transaction overview, parties involved, financial data of the target company, transaction terms, and the strategic rationale and impact on the company. The document is structured as a formal announcement to shareholders and the public about a capital investment and acquisition transaction. It does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, audit report, or earnings release. The content fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising, financing activities, and capital structure changes related to the acquisition and capital increase. The document length (5620 characters) and detailed transaction information support this classification with high confidence.
2015-11-25 Chinese
2015年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2015 Third Quarter Report" of Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains detailed financial data including balance sheets, income statements, cash flow information, shareholder information, and management's discussion of financial performance for the third quarter of 2015. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2015
2015-10-25 Chinese
2015年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2015 Third Quarter Report" of Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains detailed financial data for the third quarter of 2015, including major accounting data, financial indicators, shareholder information, changes in financial statement items, and management's discussion on performance and outlook. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarterly) confirms it is an Interim / Quarterly Report. The document length is over 12,000 characters, indicating it is the full report, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2015
2015-10-25 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.